the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
July 16, 2023 – For months, it has been considered the slimming miracle elixir: the pharmac0logically active ingredient Semaglutide. Semaglutide is a GLP-1 receptor agonist, which means it mimics the action of human incretin glucagon-like peptide-1 (GLP-1). This improves insulin …
July 07, 2017 – A new study analyzing genetic mutations predisposing to increased body-mass index (BMI) provides strong evidence that higher BMI plays a causal role in type 2 diabetes, hypertension, and coronary heart disease (CHD). The study results strongly suggest …
Genetic Study Strengthens Causal Role of BMI in Heart Disease Read more »
December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use …
The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA Read more »
September 13, 2014 – The U.S. Food and Drug Administration approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for …